yahoo.comAUG 231 min read$CAH

Cardinal Health's CEO Moved 124,529 Shares in Two Days. Here's What Long-Term Investors Should Know

Cardinal Health's CEO sold 124,529 shares in two days, totaling $29.4 million, following the vesting of restricted stock. The company reported fiscal 2026 revenue of $254 billion, up 14%, and $5 billion in adjusted free cash flow. Non-GAAP earnings per share have more than doubled since fiscal 2022. However, the medical products and distribution segment faces challenges due to tariff relief and rising costs.

Original reporting

yahoo.com

Published Aug 23, 2026, 11:15 AM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 23, 2026, 11:19 AM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

Cardinal Health's CEO Moved 124,529 Shares in Two Days. Here's What Long-Term Investors Should Know — source image — Source · yahoo.com

Decision brief

The 30-second read

$CAHBearishLow

Why it matters

The CEO's insider sale adds a modest negative catalyst amid otherwise positive fundamentals.

Market read

While the insider sale is new information, its scale is limited; traders may watch for short-term price reaction.

What to watch

Recent strong earnings and buyback authorization may offset negative sentiment.

Relevance 5/10Novelty 5/10Timing: reported today

Background

Cardinal Health reported strong FY2026 results with revenue up 14% and a $5 billion buyback authorization.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CAHBearishMedium confidence

Context

CEO Michael Hollar sold 124,529 shares over two days, a new Form 4 filing disclosed on Aug 23 2026.

Expected impact

Potential modest downside pressure in the next few trading sessions.

Evidence & confidence

Insider sales often lead to short-term sell pressure, but the amount is modest relative to market cap.

Market effects

Sector

Minimal impact on the broader healthcare distribution sector.

Regional

Limited to US markets where Cardinal Health trades.

Global

Low; the news is company‑specific.

Counterpoint

What could challenge this read

The sale could be routine diversification and not indicative of future performance.

Key entities

Company
Cardinal Health
U.S. healthcare services and products distributor (ticker CAH).
Executive
Michael Hollar
Chief Executive Officer of Cardinal Health.

Read at source ← All news

SEP 7

$CAHMedAI 8/10

4 companies on verge of settling US opioid lawsuits

AmerisourceBergen, Cardinal Health, McKesson, and Johnson & Johnson are nearing a $26B settlement for opioid lawsuits. New York reached a separate $1B deal with the distributors. Johnson & Johnson will contribute up to $5B nationally. Trials continue elsewhere.

pressdemocrat.com3 min

SEP 3

$CAHHighAI 8/10

Jim Cramer Notes Cardinal Health (CAH) is “Too Attractive to Ignore”

Jim Cramer highlighted Cardinal Health (CAH) as a favorite, citing its specialty pharmaceuticals and healthcare services growth. Q4 revenue rose 6% to $63.7B but missed estimates, while adjusted EPS was $2.91. Fiscal 2027 guidance includes non-GAAP EPS of $12.40-$12.60 and adjusted free cash flow of $3.5B-$4B. Risks include execution, drug pricing, and customer concentration.

insidermonkey.com3 min

AUG 19

$CAHHighAI 8/10

Cardinal Health’s (CAH) Big Earnings Beat Hides a More Complicated Story

Cardinal Health (CAH) reported Q4 2026 earnings with non-GAAP EPS up 40% YoY to $2.91, including a $0.31 one-time tariff refund. Revenue reached $63.7B, up 6% YoY. Full-year adjusted free cash flow hit $5B. Guidance suggests slower growth ahead. The company expanded its buyback program by $5B to $6.4B.

yahoo.com2 min

AUG 18

$CAHHighAI 9/10

Cardinal Health (CAH) Q4 2026 Earnings Call Transcript

Cardinal Health (CAH) reported Q4 2026 revenue of $63.7B, up 6%, driven by Pharmaceutical and Specialty Solutions. Non-GAAP EPS was $2.91, up 40%. Fiscal 2027 guidance includes 3-5% pharma revenue growth and 8-11% profit growth. The company plans $1B in share repurchases and increased its authorization to $6.4B. Management cited risks from geopolitical instability and IRA price changes.

fool.com6 min

AUG 18

$CAHMed

5 Revealing Analyst Questions From Cardinal Health’s Q2 Earnings Call

Cardinal Health reported Q2 revenue of $63.67B, below Wall Street’s $65.42B estimate, but adjusted EPS of $2.60 beat the $2.42 estimate. Management cited demand in Pharmaceutical and Specialty Solutions and progress on its improvement plan in Global Medical Products and Distribution. Guidance for FY2027 adjusted EPS midpoint was $12.50. Analysts asked about specialty growth, M&A, regulatory impacts, and input costs.

financialcontent.com7 min

AUG 17

$BAXMed

Baxter’s interim CFO is leaving for Cardinal Health

Baxter said in SEC filings that interim CFO Anita Zielinski will leave in September. She will join Cardinal Health as chief accounting officer and SVP of finance on Nov. 5, with a $750,000 sign-on bonus and $1 million in time-vesting RSUs. Baxter has not named a successor. Baxter recently raised its full-year outlook to 3%-4% sales growth and adjusted EPS of $1.95-$2.15.

massdevice.com4 min